CG Oncology jumps after late-stage bladder cancer therapy data

Shares of cancer drug developer CG Oncology CGON.O rise 34% to $30

On late Saturday, CGON said its bladder cancer therapy, cretostimogene grenadenorepvec, showed 42.3% of patients maintained complete response at 24 months for high-risk bladder cancer patients who failed previous treatments, in an ongoing late-stage study

97.3% of treated patients remained free from progression to more serious muscle-invasive bladder cancer at 24 months, co said

Early data from another patient group, Cohort P, showed 90.5% of patients remained free from high-grade recurrence at both 3 and 9 months

As of last close, stock down 22% YTD